Noah D Kauff

Summary

Affiliation: Memorial Sloan-Kettering Cancer Center
Country: USA

Publications

  1. ncbi request reprint Is It time to stratify for BRCA mutation status in therapeutic trials in ovarian cancer?
    Noah D Kauff
    J Clin Oncol 26:9-10. 2008
  2. pmc Common breast cancer susceptibility alleles are associated with tumour subtypes in BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2
    Anna Marie Mulligan
    Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, 2 Worts Causeway, Cambridge, CB1 8RN, UK
    Breast Cancer Res 13:R110. 2011
  3. ncbi request reprint Risk-reducing salpingo-oophorectomy in patients with germline mutations in BRCA1 or BRCA2
    Noah D Kauff
    Gynecology Service, Department of Surgery, and Clinical Genetics Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 25:2921-7. 2007
  4. ncbi request reprint Ovarian carcinoma screening in women at intermediate risk: impact on quality of life and need for invasive follow-up
    Noah D Kauff
    Gynecology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Cancer 104:314-20. 2005
  5. pmc Risk-reducing salpingo-oophorectomy for the prevention of BRCA1- and BRCA2-associated breast and gynecologic cancer: a multicenter, prospective study
    Noah D Kauff
    Clinical Genetics and Gynecology Services, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, Box 192, New York, NY 10021, USA
    J Clin Oncol 26:1331-7. 2008
  6. ncbi request reprint Risk of ovarian cancer in BRCA1 and BRCA2 mutation-negative hereditary breast cancer families
    Noah D Kauff
    Department of Gynecology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Natl Cancer Inst 97:1382-4. 2005
  7. doi request reprint Absence of genomic BRCA1 and BRCA2 rearrangements in Ashkenazi breast and ovarian cancer families
    Zsofia K Stadler
    Department of Medicine, Clinical Genetics Service, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, Box 192, New York, NY 10021, USA
    Breast Cancer Res Treat 123:581-5. 2010
  8. ncbi request reprint Frequency of BRCA1 and BRCA2 mutations in unselected Ashkenazi Jewish patients with colorectal cancer
    Tomas Kirchhoff
    Clinical Genetics Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Natl Cancer Inst 96:68-70. 2004
  9. ncbi request reprint BRCA mutations and risk of prostate cancer in Ashkenazi Jews
    Tomas Kirchhoff
    Clinical Genetics Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Clin Cancer Res 10:2918-21. 2004
  10. pmc Outcomes of primary surgical cytoreduction in patients with BRCA-associated high-grade serous ovarian carcinoma
    David M Hyman
    Gynecologic Medical Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, 300 E 66th Street, New York, NY 10065, USA
    Gynecol Oncol 126:224-8. 2012

Research Grants

Detail Information

Publications35

  1. ncbi request reprint Is It time to stratify for BRCA mutation status in therapeutic trials in ovarian cancer?
    Noah D Kauff
    J Clin Oncol 26:9-10. 2008
  2. pmc Common breast cancer susceptibility alleles are associated with tumour subtypes in BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2
    Anna Marie Mulligan
    Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, 2 Worts Causeway, Cambridge, CB1 8RN, UK
    Breast Cancer Res 13:R110. 2011
    ..It is currently unknown how these alleles are associated with different breast cancer subtypes in BRCA1 and BRCA2 mutation carriers defined by estrogen (ER) or progesterone receptor (PR) status of the tumour...
  3. ncbi request reprint Risk-reducing salpingo-oophorectomy in patients with germline mutations in BRCA1 or BRCA2
    Noah D Kauff
    Gynecology Service, Department of Surgery, and Clinical Genetics Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 25:2921-7. 2007
    ..Considerations that may impact the appropriate timing of the procedure will be reviewed, and the potential role of RRSO in BRCA-negative hereditary breast cancer families will also be discussed...
  4. ncbi request reprint Ovarian carcinoma screening in women at intermediate risk: impact on quality of life and need for invasive follow-up
    Noah D Kauff
    Gynecology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Cancer 104:314-20. 2005
    ..Limited information is available regarding the impact of this approach on either quality of life (QOL) or need for invasive follow-up in this group of women...
  5. pmc Risk-reducing salpingo-oophorectomy for the prevention of BRCA1- and BRCA2-associated breast and gynecologic cancer: a multicenter, prospective study
    Noah D Kauff
    Clinical Genetics and Gynecology Services, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, Box 192, New York, NY 10021, USA
    J Clin Oncol 26:1331-7. 2008
    ....
  6. ncbi request reprint Risk of ovarian cancer in BRCA1 and BRCA2 mutation-negative hereditary breast cancer families
    Noah D Kauff
    Department of Gynecology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Natl Cancer Inst 97:1382-4. 2005
    ..66 was expected (SIR = 1.52, 95% CI = 0.02 to 8.46; P = .48). These results suggest that women from BRCA mutation-negative, site-specific breast cancer families are not at increased risk for ovarian cancer...
  7. doi request reprint Absence of genomic BRCA1 and BRCA2 rearrangements in Ashkenazi breast and ovarian cancer families
    Zsofia K Stadler
    Department of Medicine, Clinical Genetics Service, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, Box 192, New York, NY 10021, USA
    Breast Cancer Res Treat 123:581-5. 2010
    ..Major gene rearrangements involving the BRCA1 and BRCA2 genes appear to contribute little to the burden of inherited predisposition to breast and ovarian cancer in the Ashkenazim...
  8. ncbi request reprint Frequency of BRCA1 and BRCA2 mutations in unselected Ashkenazi Jewish patients with colorectal cancer
    Tomas Kirchhoff
    Clinical Genetics Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Natl Cancer Inst 96:68-70. 2004
    ..22 to 1.14). We thus recommend that counseling for colorectal cancer screening and prevention in individuals with BRCA mutations be based on the personal and family history of colorectal cancer or associated syndromic malignancies...
  9. ncbi request reprint BRCA mutations and risk of prostate cancer in Ashkenazi Jews
    Tomas Kirchhoff
    Clinical Genetics Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Clin Cancer Res 10:2918-21. 2004
    ..Several series looking at the frequency of BRCA mutations in unselected patients with prostate cancer have not confirmed this finding. To clarify this issue, we conducted a large case-control study...
  10. pmc Outcomes of primary surgical cytoreduction in patients with BRCA-associated high-grade serous ovarian carcinoma
    David M Hyman
    Gynecologic Medical Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, 300 E 66th Street, New York, NY 10065, USA
    Gynecol Oncol 126:224-8. 2012
    ..BRCA-associated and sporadic ovarian cancers have different pathologic and clinical features. Our goal was to determine if BRCA mutation status is an independent predictor of residual tumor volume following primary surgical cytoreduction...
  11. doi request reprint Morphologic patterns associated with BRCA1 and BRCA2 genotype in ovarian carcinoma
    Robert A Soslow
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Mod Pathol 25:625-36. 2012
    ..60 (95% CI, 0.32-0.84) and a negative predictive value of 1.0 (95% CI, 0.63-1.0)). These preliminary data indicate potential strong associations between morphology and genotype in high-grade serous carcinomas...
  12. ncbi request reprint Ovarian cancer risk in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations
    Jaya M Satagopan
    Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Clin Cancer Res 8:3776-81. 2002
    ..To address this, we have used a case-control design that does not involve familial aggregation to estimate the lifetime penetrance of ovarian cancer due to BRCA1 and BRCA2 mutations...
  13. pmc Genome-wide association studies of cancer
    Zsofia K Stadler
    Clinical Genetics Service andthe Cancer Biology and Genetics Program, Memorial Sloan Kettering Cancer Center, NY, NY 10021, USA
    J Clin Oncol 28:4255-67. 2010
    ..To date, however, the clinical utility of GWAS-derived risk markers remains limited...
  14. ncbi request reprint Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation
    Noah D Kauff
    Clinical Genetics Service, Memorial Sloan Kettering Cancer Center, New York 10021, USA
    N Engl J Med 346:1609-15. 2002
    ..We prospectively compared the effect of risk-reducing salpingo-oophorectomy with that of surveillance for ovarian cancer on the incidence of subsequent breast cancer and BRCA-related gynecologic cancers in women with BRCA mutations...
  15. pmc Improved survival for BRCA2-associated serous ovarian cancer compared with both BRCA-negative and BRCA1-associated serous ovarian cancer
    David M Hyman
    Gynecologic Medical Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA
    Cancer 118:3703-9. 2012
    ..The objective of the current study was to examine whether BRCA1-associated and BRCA2-associated ovarian cancers were associated with different outcomes...
  16. doi request reprint Prevalence of BRCA1 and BRCA2 mutations in Ashkenazi Jewish families with breast and pancreatic cancer
    Zsofia K Stadler
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    Cancer 118:493-9. 2012
    ..Breast-pancreas cancer families with BRCA1 mutations have also been observed. The influence of a family history (FH) of PC on BRCA mutation prevalence in patients with breast cancer (BC) is unknown...
  17. ncbi request reprint Hereditary ovarian cancer in Ashkenazi Jews
    Luis Robles-Díaz
    Clinical Genetics Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Fam Cancer 3:259-64. 2004
    ..Ovarian cancer in Ashkenazi kindreds has served as a model for the study of the histopathology of inherited ovarian cancers as well as for the study of risk reduction and screening among all women at inherited risk of ovarian cancer...
  18. ncbi request reprint Effect of mammography on breast cancer risk in women with mutations in BRCA1 or BRCA2
    Deborah Goldfrank
    Clinical Genetics Service, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Cancer Epidemiol Biomarkers Prev 15:2311-3. 2006
    ..08; P = 0.03). These findings indicate that screening mammography is unlikely to be associated with a large increase in breast cancer risk in this population...
  19. ncbi request reprint Clinical outcome of isolated serous tubal intraepithelial carcinomas (STIC)
    Stephanie L Wethington
    Department of Surgery, Gynecology Service, Department of Pathology, and Clinical Genetics Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY and Weill Cornell Medical College, New York, NY
    Int J Gynecol Cancer 23:1603-11. 2013
    ..Serous tubal intraepithelial carcinoma (STIC) is a pathologic finding of unknown clinical significance. This study evaluates the clinical outcome of patients with isolated STIC...
  20. ncbi request reprint Pre- and postmenopausal high-risk women undergoing screening for ovarian cancer: anxiety, risk perceptions, and quality of life
    Martee L Hensley
    Department of Medicine, Memorial Sloan Kettering Cancer Center, 1278 York Avenue, New York, NY 10021 6094, USA
    Gynecol Oncol 89:440-6. 2003
    ..We sought to determine whether anxiety, depression, perception of ovarian cancer risk, and false-positive test frequency differed between high-risk premenopausal and postmenopausal women initiating ovarian cancer screening...
  21. ncbi request reprint Epithelial lesions in prophylactic mastectomy specimens from women with BRCA mutations
    Noah D Kauff
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Cancer 97:1601-8. 2003
    ....
  22. ncbi request reprint Screening and prevention of hereditary gynecologic cancers
    Siobhan M Kehoe
    Gynecology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Semin Oncol 34:406-10. 2007
    ..Additionally, we outline ongoing questions and areas for future research...
  23. doi request reprint Genome-wide association studies of cancer predisposition
    Zsofia K Stadler
    Clinical Genetics Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Hematol Oncol Clin North Am 24:973-96. 2010
    ..Studies involving more heterogeneous populations, determination of the causal variants, and functional studies are now necessary to further elucidate the potential biologic and clinical significance of the observed associations...
  24. ncbi request reprint Laparoscopic bilateral salpingo-oophorectomy in breast cancer patients after transverse rectus abdominus myocutaneous flap reconstructive surgery
    Christopher S Awtrey
    Gynecology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Gynecol Oncol 99:720-5. 2005
    ....
  25. pmc Topotecan in patients with BRCA-associated and sporadic platinum-resistant ovarian, fallopian tube, and primary peritoneal cancers
    David M Hyman
    Gynecologic Medical Oncology Service, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Gynecol Oncol 123:196-9. 2011
    ..To evaluate the efficacy of topoisomerase I inhibitor, topotecan, in patients with recurrent BRCA+ versus BRCA- ovarian, fallopian tube, and primary peritoneal carcinomas...
  26. ncbi request reprint Hereditary ovarian cancer: recent molecular insights and their impact on screening strategies
    Kara C Long
    aGynecology Service, Department of Surgery bClinical Genetics Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    Curr Opin Oncol 23:526-30. 2011
    ..This review will focus on the implications of BRCA status in the patient with high-grade serous ovarian cancer, the differences between BRCA1 and BRCA2 mutations, and the most effective risk-reducing strategies...
  27. ncbi request reprint Rare variants of ATM and risk for Hodgkin's disease and radiation-associated breast cancers
    Kenneth Offit
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Clin Cancer Res 8:3813-9. 2002
    ..We next sought to determine the frequency of ATM variants in patients with Hodgkin's lymphoma, regardless of coexisting BC, compared with healthy volunteers...
  28. ncbi request reprint Assessment of individuals with BRCA1 and BRCA2 large rearrangements in high-risk breast and ovarian cancer families
    Angela G Arnold
    Memorial Sloan Kettering Cancer Center, New York, NY, 10065, USA
    Breast Cancer Res Treat 145:625-34. 2014
    ..Our study shows that BRCA1/2 LR testing should be offered to all women who meet criteria for BRCA1/2 sequence analysis...
  29. doi request reprint Selection of endometrial carcinomas for DNA mismatch repair protein immunohistochemistry using patient age and tumor morphology enhances detection of mismatch repair abnormalities
    Karuna Garg
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Am J Surg Pathol 33:925-33. 2009
    ..Tumor morphology (TM-MMR) along with IHC-MMR enhances the detection of EC patients at risk of HNPCC...
  30. ncbi request reprint Surgical risk-reduction in carriers of BRCA mutations: where do we go from here?
    Noah D Kauff
    Gynecol Oncol 93:277-9. 2004
  31. ncbi request reprint Society of Gynecologic Oncologists Education Committee statement on risk assessment for inherited gynecologic cancer predispositions
    Johnathan M Lancaster
    H Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA
    Gynecol Oncol 107:159-62. 2007
    ..This commentary provides guidance on identification of patients who may benefit from hereditary cancer risk assessment for Hereditary Breast/Ovarian Cancer and the Lynch/Hereditary Non-Polyposis Colorectal Cancer syndrome...
  32. ncbi request reprint Reducing the risk of gynecologic cancer in the Lynch syndrome
    Kenneth Offit
    N Engl J Med 354:293-5. 2006
  33. ncbi request reprint Modeling genetic risk of breast cancer
    Noah D Kauff
    JAMA 297:2637-9. 2007
  34. ncbi request reprint Does a BRCA mutation plus tamoxifen equal hysterectomy?
    Karen H Lu
    Gynecol Oncol 104:3-4. 2007
  35. ncbi request reprint The significance of cytological mesothelial atypia diagnosed from peritoneal washings performed during risk-reducing salpingo-oophorectomy
    Ram Eitan
    Department of Obstetrics and Gynecology, Shaare Zedek Medical Center, Jerusalem, Israel
    Gynecol Oncol 102:315-8. 2006
    ..The objective of this study was to determine the significance of cytologic mesothelial atypia in the peritoneal washings of patients undergoing RRSO...

Research Grants1

  1. Structural, Computational and Epidemiologic Analyses of*
    Noah Kauff; Fiscal Year: 2006
    ..abstract_text> ..